Drug trial aims to tame severe eczema itch and rash

NCT ID NCT05999799

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study tested an injectable drug called GSK1070806 to see if it could reduce the severity of eczema (atopic dermatitis) in adults. It compared different doses of the drug against a placebo injection over 16 weeks. The main goal was to see how much the drug could reduce the extent and severity of the skin rash and itching.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Phoenix, Arizona, 85006, United States
GSK Investigational Site

North Little Rock, Arkansas, 72117, United States
GSK Investigational Site

Canoga Park, California, 91303, United States
GSK Investigational Site

Fountain Valley, California, 92708, United States
GSK Investigational Site

Northridge, California, 91325, United States
GSK Investigational Site

Oceanside, California, 92056, United States
GSK Investigational Site

Santa Monica, California, 90404, United States
GSK Investigational Site

Homestead, Florida, 33033, United States
GSK Investigational Site

Oakland Park, Florida, 33334, United States
GSK Investigational Site

Fayetteville, Georgia, 30214, United States
GSK Investigational Site

Thomasville, Georgia, 31792, United States
GSK Investigational Site

Chicago, Illinois, 60614, United States
GSK Investigational Site

Troy, Michigan, 48084, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

New York, New York, 10075, United States
GSK Investigational Site

Dublin, Ohio, 43016, United States
GSK Investigational Site

West Lake Hills, Texas, 78746, United States
GSK Investigational Site

Buenos Aires, C1055AAO, Argentina
GSK Investigational Site

Capital Federal, C1181ACH, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1056ABI, Argentina
GSK Investigational Site

Córdoba, X5000AAW, Argentina
GSK Investigational Site

Mendoza, 5500, Argentina
GSK Investigational Site

Rosario, S2002, Argentina
GSK Investigational Site

Pleven, 5800, Bulgaria
GSK Investigational Site

Sofia, 1510, Bulgaria
GSK Investigational Site

Sofia, Bulgaria
GSK Investigational Site

Kelowna, British Columbia, V1Y 4N7, Canada
GSK Investigational Site

Barrie, Ontario, L4M 7G1, Canada
GSK Investigational Site

London, Ontario, N6H 5L5, Canada
GSK Investigational Site

Markham, Ontario, L3P1X2, Canada
GSK Investigational Site

Québec, Quebec, G1W 4R4, Canada
GSK Investigational Site

Beijing, 100044, China
GSK Investigational Site

Chongqing, 400016, China
GSK Investigational Site

Fuzhou, 350014, China
GSK Investigational Site

Guangzhou, China
GSK Investigational Site

Hangzhou, 310006, China
GSK Investigational Site

Shanghai, 200025, China
GSK Investigational Site

Shanghai, China
GSK Investigational Site

Yinchuan, China
GSK Investigational Site

Yiwu, 322000, China
GSK Investigational Site

Prague, 10034, Czechia
GSK Investigational Site

Prague, 128 08, Czechia
GSK Investigational Site

Prague, Czechia
GSK Investigational Site

La Rochelle, 17019, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Berlin, 10789, Germany
GSK Investigational Site

Hamburg, 22391, Germany
GSK Investigational Site

Münster, 48149, Germany
GSK Investigational Site

Athens, Greece
GSK Investigational Site

Bari, 70124, Italy
GSK Investigational Site

Bologna, 40138, Italy
GSK Investigational Site

Florence, Italy
GSK Investigational Site

Modena, 41124, Italy
GSK Investigational Site

Roma, 00128, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Chiba, 272-0033, Japan
GSK Investigational Site

Fukuoka, 807-8556, Japan
GSK Investigational Site

Fukuoka, 812-8582, Japan
GSK Investigational Site

Gunma, 370-0829, Japan
GSK Investigational Site

Hokkaido, 060-0033, Japan
GSK Investigational Site

Hokkaido, 080-0013, Japan
GSK Investigational Site

Kanagawa, 211-0063, Japan
GSK Investigational Site

Osaka, 583-8588, Japan
GSK Investigational Site

Osaka, 593-8324, Japan
GSK Investigational Site

Saitama, 343-8555, Japan
GSK Investigational Site

Chihuahua City, 31000, Mexico
GSK Investigational Site

Durango, 34000, Mexico
GSK Investigational Site

Guadalajara, 44628, Mexico
GSK Investigational Site

Monterrey, 64718, Mexico
GSK Investigational Site

Panama City, 7099, Panama
GSK Investigational Site

Chojnice, 89-600, Poland
GSK Investigational Site

Elblag, 82-300, Poland
GSK Investigational Site

Katowice, 40-600, Poland
GSK Investigational Site

Poznan, 60-569, Poland
GSK Investigational Site

Szczecin, 70-332, Poland
GSK Investigational Site

Warsaw, 03-291, Poland
GSK Investigational Site

Ansan, 15355, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 04564, South Korea
GSK Investigational Site

Seoul, 04763, South Korea
GSK Investigational Site

Seoul, 150-950, South Korea
GSK Investigational Site

Alicante, 03010, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Granada, 18016, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Vigo, 36206, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Pathum Thani, 12120, Thailand

Conditions

Explore the condition pages connected to this study.

DERMATITIS ATOPIC